骨质疏松患者根尖周病变患病率研究
本研究基于医院患者数据,评估骨质疏松患者根尖周病变的患病率,并比较阿仑膦酸钠与利塞膦酸钠治疗者的差异。结果显示骨质疏松患者根尖周病变患病率显著升高(OR=3.36,P<.0001),而使用双膦酸盐者患病率明显降低。
要点
- 骨质疏松患者根尖周病变患病率为1.78%,显著高于一般患者的0.52%。
- 使用双膦酸盐的骨质疏松患者根尖周病变OR为2.35,低于未使用者的3.52。
- 利塞膦酸钠治疗者OR为1.34(P=.3502),阿仑膦酸钠为1.6(P<.0001)。
核心结论
- 骨质疏松患者根尖周病变患病率显著高于一般患者人群。
- 使用双膦酸盐的骨质疏松患者根尖周病变患病率明显降低,尤其是利塞膦酸钠。
研究设计与样本
- 基于医院患者综合数据的回顾性研究,检索骨质疏松和根尖周炎诊断代码。
- 共纳入1,644,953例医院患者,其中8,715例有根尖周病变,42,292例诊断骨质疏松。
主要发现
- 骨质疏松患者根尖周病变患病率为1.78%,一般患者人群为0.52%。
- 骨质疏松患者根尖周病变OR为3.36,差异有统计学意义(P<.0001)。
- 使用任何双膦酸盐的骨质疏松患者根尖周病变患病率为1.25%,一般人群为0.52%,OR差异有统计学意义(P<.0001)。
- 使用双膦酸盐的骨质疏松组根尖周病变OR为2.35,未使用双膦酸盐组为3.52,差异有统计学意义(P<.0001)。
- 阿仑膦酸钠治疗者根尖周病变OR为1.6(P<.0001),利塞膦酸钠治疗者OR为1.34(P=.3502)。
关键数值与推荐
- 骨质疏松患者根尖周病变患病率1.78%,一般患者人群0.52%。
- 骨质疏松患者根尖周病变OR=3.36(P<.0001)。
- 使用双膦酸盐的骨质疏松患者根尖周病变OR=2.35,未使用者OR=3.52(P<.0001)。
- 阿仑膦酸钠治疗者OR=1.6(P<.0001),利塞膦酸钠治疗者OR=1.34(P=.3502)。
临床怎么用
- 对骨质疏松患者应关注根尖周病变的筛查与预防。
- 使用双膦酸盐的骨质疏松患者根尖周病变风险相对较低,但仍需定期口腔检查。
局限性
- 本研究基于医院诊断代码数据,可能存在编码偏倚。
- 研究为回顾性设计,无法确定因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Osteoporosis is a major systemic disease that can significantly deteriorate the quality of life of the affected individuals. It is more common in women, particularly after menopause. Osteoporosis may be associated with alterations in oral health. Treatment of osteoporotic patients mainly involves the administration of bisphosphonates (BPs). Nitrogen-containing BPs are more potent therapeutically and more commonly used. The purpose of this study was to assess the prevalence of periapical lesions in patients with osteoporosis and to evaluate the difference in the prevalence of periapical lesions in patients treated with alendronate and risedronate, 2 nitrogen-containing types of BPs. METHODS: Integrated data of hospital patients were used. Data from the corresponding diagnosis codes for osteoporosis and periapical periodontitis were retrieved by searching the appropriate query in the database. The odds ratio (OR) of periapical lesions, its association with osteoporosis, and the use of 2 BP medications were calculated and analyzed statistically. RESULTS: Of 1,644,953 hospital patients, 8715 presented with periapical lesions. A total of 42,292 patients were diagnosed with osteoporosis. A total of 754 patients diagnosed with osteoporosis presented with periapical lesions. The prevalence of periapical lesions in patients with osteoporosis was 1.78% compared with 0.52% in the general patient population of the hospital. The OR for the prevalence of periapical lesions in patients with osteoporosis was 3.36 and was statistically significant (P < .0001). Patients with osteoporosis treated with any type of BPs showed a prevalence of periapical lesions in 1.25% of cases compared with 0.52% in the general patient population of the hospital. The difference in the OR was statistically significant (P < .0001). The OR for the presence of periapical lesions in the osteoporosis group treated with BPs was 2.35 compared with 3.52 in the osteoporosis group not treated with BP. The difference in the OR was statistically significant (P < .0001). Patients treated with alendronate showed an OR of 1.6 for the prevalence of periapical lesions, and the difference in the OR was statistically significant (P < .0001). Patients treated with risedronate showed an OR of 1.34 for the prevalence of periapical lesions, and the difference in the OR was not statistically significant (P = .3502). CONCLUSIONS: Under the conditions of this study, it appears that the prevalence of periapical lesions is significantly higher in osteoporotic patients. Osteoporotic patients treated with BPs showed a marked reduction in the prevalence of periapical lesions, especially when risedronate was used.
引用
- Katz J, Rotstein I. Prevalence of Periapical Lesions in Patients with Osteoporosis. J Endod. 2020. PMID: 33130060. doi:10.1016/j.joen.2020.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。